High-risk medulloblastoma: does c-myc amplification overrule histopathology?
- PMID: 20063409
- PMCID: PMC4517433
- DOI: 10.1002/pbc.22398
High-risk medulloblastoma: does c-myc amplification overrule histopathology?
Comment on
-
Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.Pediatr Blood Cancer. 2010 Mar;54(3):369-76. doi: 10.1002/pbc.22339. Pediatr Blood Cancer. 2010. PMID: 19908297
References
-
- Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24:4202–4208. - PubMed
-
- Pfister S, Remke M, Benner A, et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol. 2009;27:1627–1636. - PubMed
-
- Giangaspero F, Eberhart CG, Haapasalo H, et al. Medulloblastoma. In: Louis DN, Hirolo O, Wiester OD, Cavenee WK, editors. WHO classification of tumours of the central nervous system. Lyon, France: International Agency for Research on Cancer; 2007. pp. 132–140.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical